Immunic, Inc. to Participate in Scientific and Industry Conferences in April ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Immunic (IMUX – Research Report) received a Buy rating and a $1.20 price target from William Blair analyst Matt Phipps yesterday. The company’s ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Analysts at William Blair issued their FY2026 EPS estimates for shares of Immunic in a research note issued to investors on ...

Immunic (NASDAQ:IMUX – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to ...

So should Immunic (NASDAQ:IMUX) shareholders be worried about its cash burn? In this article, we define cash burn as its annual (negative) free cash flow, which is the amount of money a company ...

In a challenging market environment, Immunic, Inc. (NASDAQ:IMUX) stock has recorded a new 52-week low, dipping to $0.92. The biopharmaceutical company, which focuses on developing treatments for ...

Short interest in Immunic Inc (NASDAQ:IMUX) decreased during the last reporting period, falling from 2.55M to 2.40M. This put 2.69% of the company's publicly available shares short. Short interest ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced ...